Nonalcoholic steatohepatitis (NASH) is a progressive liver disorder caused by excessive fat accumulation, which leads to inflammation and fibrosis. Without proper intervention, it can advance to cirrhosis and liver failure. As an advanced stage of nonalcoholic fatty liver disease (NAFLD), NASH is strongly linked to metabolic dysfunction and obesity. The increasing NASH prevalence has placed it at the center of global health concerns, driving extensive research efforts.
Understanding the NASH Epidemic
The rise in NASH prevalence is largely due to increasing rates of obesity and diabetes, alongside poor lifestyle habits. Once considered rare, NASH is now a leading cause of liver transplants worldwide, making the development of effective treatments a priority.
Potential Treatments on the Horizon
Currently, there are no FDA-approved drugs for NASH, but promising drug candidates are in development. Some of the most notable therapeutic approaches include:
- FXR Agonists – Reduce liver fat and inflammation through bile acid regulation.
- GLP-1 Receptor Agonists – Improve metabolic function and promote weight loss.
- PPAR Agonists – Help modulate lipid metabolism and inflammation.
- Thyroid Hormone Receptor-Beta Agonists – Target liver fat accumulation.
The Future of NASH Treatment
The rapid growth of research in the field is set to transform NASH management. With increasing pharmaceutical investment, efforts are focused on early diagnosis and innovative therapies. As the NASH prevalence continues to rise, researchers are dedicated to tackling NASH effectively and improving patient outcomes.
Latest Reports Offered By Delveinsight
Attention Deficit Hyperactivity Disorder Market | Lactose Intolerance Market | Urea Cycle Disorders Market | Overactive Bladder Syndrome Market | Surgical Energy Instruments Market | Pipeline Assessment Services | Penile Cancer Market | Total Knee Arthroplasty Market | Indwelling Catheters Market
Contact Information
Kanishk
kkumar@delveinsight.com
